The present invention provides compounds of formula I, and
pharmaceutically acceptable salts thereof The formula I compounds inhibit
the tyrosine kinase activity of growth factor receptors such as VEGFR-2
and FGFR-1, thereby making them useful as anti-cancer agents. The formula
I compounds are also useful for the treatment of other diseases
associated with signal transduction pathways operating through growth
factor receptors.